<DOC>
	<DOCNO>NCT02036086</DOCNO>
	<brief_summary>This study evaluate clinical pathological response vemurafenib cobimetinib neoadjuvant treatment patient histologically confirm , BRAF V600 mutation-positive Stage IIIB C melanoma . 20 patient treat vemurafenib cobimetinib 2 month . Then assess surgery . Patients undergo surgery subsequently resume take vemurafenib cobimetinib recovery surgery . Patients undergo radiation therapy appropriate continue vemurafenib cobimetinib . The maximum treatment period 12 month . After 12 month treatment , patient follow disease recurrence survival total 5 year .</brief_summary>
	<brief_title>Study Neo-adjuvant Use Vemurafenib Plus Cobimetinib BRAF Mutant Melanoma With Palpable Lymph Node Metastases</brief_title>
	<detailed_description>At Screening : Assessments include CT MRI brain , CT chest , abdomen pelvis , dermatology assessment , head neck exam , pelvic anal exam , ophthalmology exam , electrocardiogram ( ECG ) , echocardiogram ( ECHO ) multigated acquisition ( MUGA ) scan , history physical exam . A core biopsy perform within 14 day study entry . During Treatment : The maximum treatment period 12 month . Patients assess monthly treatment . Assessments perform include vital sign assessment physical exam , dermatology exam , ophthalmology exam , echocardiogram ( ECHO ) multigated acquisition ( MUGA ) scan , electrocardiogram ( ECG ) , safety blood test , pelvic anal exam . Follow-up treatment : Patients follow 5 year . Radiology exams do assess disease . Other assessment perform include vital sign assessment physical exam , dermatology exam , include echogram ( ECHO ) multigated acquisition ( MUGA ) scan .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>1 . Naïve treatment locally advance unresectable disease ( Stage IIIB C ) . Prior adjuvant therapy ( include immunotherapy , e.g. , Ipilimumab ) allow prior nodal recurrence . 2 . Biopsy proven unresected melanoma palpable regional lymph node metastasis , stage IIIB C recurrent regional lymphadenopathy suitable preferred surgical intervention . 3 . BRAFV600 mutation positive 4 . Eastern Cooperative Oncology Group performance status 0 1 5 . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 6 . Adequate hematologic , renal liver function within 7 day prior first dose vemurafenib . 7 . Agree always use effective form ( ) contraception begin informed consent signature date least 6 month completion study therapy 8 . Negative serum pregnancy test within 14 day prior start treatment woman childbearing potential . 1 . Can receive prior therapy . Previous adjuvant immunotherapy allow 3 month elapse prior nodal recurrence . 2 . History prior RAF MEK pathway inhibitor treatment . 3 . Active malignancy ( BRAF−mutated melanoma ) previous malignancy within past 3 year exclude ; except patient resect melanoma , resect basal cell carcinoma ( BCC ) , resect cutaneous squamous cell carcinoma ( SCC ) , resect melanoma situ , resect carcinoma insitu cervix , resect carcinoma insitu breast . 4 . Evidence distant metastatic disease . 5 . History clinically significant liver disease ( include cirrhosis ) , current alcohol abuse , know infection Human Immunodeficiency Virus ( HIV ) , hepatitis B virus , hepatitis C virus . 6 . Active infection chronic infection require chronic suppressive antibiotic 7 . Pregnant breastfeed 8 . Active autoimmune disease 9 . Acromegaly 10 . History malabsorption clinically significant metabolic dysfunction 11 . Requires concomitant medication dietary supplement prohibit study 12 . Current , recent ( within 28 day enrolment ) plan use investigational product outside study 13 . The following food supplement prohibit least 7 day prior initiation study treatment : 1 . St. John 's wort hyperforin 2 . Grapefruit juice 14 . History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment / central serous chorioretinopathy ( CSCR ) , retinal vein occlusion ( RVO ) , neovascular macular degeneration . 15 . Risk factor retinal vein occlusion ( RVO ) base follow : 1 . Uncontrolled glaucoma intraocular pressure 2 . Serum cholesterol ≥Grade 2 3 . Hypertriglyceridemia ≥Grade 2 4 . Hyperglycemia ( fast ) ≥Grade 2 16 . Clinically significant cardiac dysfunction , include follow : 1 . Current unstable angina 2 . Current symptomatic congestive heart failure New York Heart Association class 2 high 3 . History congenital long QT syndrome correct QT interval great 450 msec baseline uncorrectable abnormality serum electrolyte ( sodium , potassium , calcium , magnesium , phosphorus ) . 4 . Current uncontrolled hypertension ≥Grade 2 ( patient history hypertension control antihypertensive ≤ Grade 1 eligible ) . 5 . Left ventricular ejection fraction ( LVEF ) institutional low limit normal ( LLN ) 50 % , whichever low 17 . Palliative radiotherapy major surgery within 14 day prior first dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Melanoma stage IIIB C BRAF mutation</keyword>
	<keyword>Recurrent regional lymphadenopathy suitable surgery</keyword>
	<keyword>Eligible neoadjuvant vemurafenib cobimetinib</keyword>
</DOC>